What this is
- How it works
- How it works isn't classified yet
- Tested for
- Ovarian Cancer, Solid Tumors
- Main trialPhase 1/2
- “The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853 stays in their blood over time. The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple…”In the company’s words, NCT06390995 on ClinicalTrials.gov
- Other names
- Mirvetuximab Soravtansine
Other drugs for Ovarian Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Mirvetuximab SoravtansineAbbVie · Phase 3
- AzenosertibK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- OregovomabCanariaBio Inc. · Phase 3
- JSKN003Alphamab · JMT-Bio · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 16 Apr 2025 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026